Business Description
Shield Therapeutics PLC
ISIN : GB00BYV81293
Description
Financial Strength
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 2.36 | |||||
Equity-to-Asset | 0.65 | |||||
Debt-to-Equity | 0.21 | |||||
Debt-to-EBITDA | -0.17 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -14.65 | |||||
Beneish M-Score | -8.39 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 46.8 | |||||
3-Year EBITDA Growth Rate | -43.6 | |||||
3-Year EPS without NRI Growth Rate | -15.1 | |||||
3-Year FCF Growth Rate | -22.1 | |||||
3-Year Book Growth Rate | -57.1 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 1.67 | |||||
9-Day RSI | 7.48 | |||||
14-Day RSI | 12.76 | |||||
6-1 Month Momentum % | -65.08 | |||||
12-1 Month Momentum % | -69.66 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.95 | |||||
Quick Ratio | 2.64 | |||||
Cash Ratio | 1.53 | |||||
Days Inventory | 198.56 | |||||
Days Sales Outstanding | 324.65 | |||||
Days Payable | 451.48 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -29.1 | |||||
Shareholder Yield % | -225.12 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 44.79 | |||||
Operating Margin % | -358.9 | |||||
Net Margin % | -613.08 | |||||
FCF Margin % | -401.31 | |||||
ROE % | -174.79 | |||||
ROA % | -114.29 | |||||
ROIC % | -96.48 | |||||
ROC (Joel Greenblatt) % | -1484.38 | |||||
ROCE % | -141.8 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 1.13 | |||||
PB Ratio | 0.39 | |||||
Price-to-Tangible-Book | 0.71 | |||||
EV-to-EBIT | -0.09 | |||||
EV-to-Forward-EBIT | -0.72 | |||||
EV-to-EBITDA | -0.1 | |||||
EV-to-Forward-EBITDA | -0.22 | |||||
EV-to-Revenue | 0.54 | |||||
EV-to-Forward-Revenue | 0.05 | |||||
EV-to-FCF | -0.15 | |||||
Price-to-Net-Current-Asset-Value | 0.71 | |||||
Earnings Yield (Greenblatt) % | -1117.7 | |||||
FCF Yield % | -222.8 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Shield Therapeutics PLC Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil £) | 6.187 | ||
EPS (TTM) (£) | -0.12 | ||
Beta | 2.74 | ||
Volatility % | 101.73 | ||
14-Day RSI | 12.76 | ||
14-Day ATR (£) | 0.001333 | ||
20-Day SMA (£) | 0.016878 | ||
12-1 Month Momentum % | -69.66 | ||
52-Week Range (£) | 0.014 - 0.1285 | ||
Shares Outstanding (Mil) | 782.06 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Shield Therapeutics PLC Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Shield Therapeutics PLC Stock Events
Event | Date | Price(£) | ||
---|---|---|---|---|
No Event Data |
Shield Therapeutics PLC Frequently Asked Questions
What is Shield Therapeutics PLC(LSE:STX)'s stock price today?
When is next earnings date of Shield Therapeutics PLC(LSE:STX)?
Does Shield Therapeutics PLC(LSE:STX) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |